Shanghai, China

Ruirui Sui

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Shanghai Hyamab Biotech Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 18.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ruirui Sui: Innovator in Antibody Development

Introduction

Ruirui Sui is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Ruirui Sui holds a patent for the invention titled "NKG2A Antibody, Preparation Method Therefor and Application Thereof." This patent highlights his focus on creating novel therapeutic solutions that can potentially improve patient outcomes in various medical conditions. The patent reflects his commitment to research and innovation in the biotechnology sector.

Career Highlights

Ruirui Sui is currently employed at Shanghai Hyamab Biotech Co., Ltd. His role at the company allows him to collaborate with other talented professionals in the field. His work is characterized by a strong emphasis on research and development, which has positioned him as a key player in the biotechnology industry.

Collaborations

Ruirui has worked alongside notable colleagues such as Qing Duan and Lile Liu. These collaborations have fostered a dynamic environment for innovation and have contributed to the success of their projects.

Conclusion

Ruirui Sui is an accomplished inventor whose work in antibody development is paving the way for future advancements in biotechnology. His patent and collaborations reflect his dedication to improving healthcare through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…